Abstract: The present invention relates to the surprising discovery that the combination of several agents, each well known for its established role in treating cancer, inflammation, hemostasis, bone resorption or serving as a solubilizing vehicle, results in a synergistic anti-cancer composition. Furthermore, the combination of at least three agents allows the cytotoxic agent, such as cyclophosphamide, to be used at a lower dosage than when administered alone. One predicted consequence of this treatment, therefore, is a highly desirable reduction in toxic side effects due to the cytotoxic agent.

Abstract: This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

Abstract: This invention relates to novel pharmaceutical compositions mixing one or more effectors (anionic impermeable molecules) with a counter ion to the effector (a liquid forming cation). The invention also relates to methods of treating or preventing diseases by administering pharmaceutical compositions to affected subjects.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.

Abstract: The invention concerns a method for the modulation of tissue-remodeling processes, by contacting the tissue to be remodeled with a compound comprising a sequence derived from certain regions of TGF-&bgr; super family Ser/Thr/kinase receptors.

Abstract: The invention concerns a method for the modulation of tissue-remodeling processes, by contacting the tissue to be remodeled with a compound comprising a sequence derived from certain regions of TGF-&bgr; super family Ser/Thr/kinase receptors.

Abstract: This invention relates to novel pharmaceutical penetration compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering penetration compositions to affected subjects.

Abstract: The present invention concerns methods for the treatment of solid tumors by the inhibition of Lyn associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn. The present invention further concerns a method for the treatment of cancer by the administration of compounds comprising Lyn-derived peptides.

Abstract: Peptides which are peptide derivatives of the &agr;D region of a protein kinase can modulate the activity of protein kinases. The activity of a protein kinase in a subject can be modulated by administering one or more of these peptides.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a protein tyrosine kinase. The peptides can modulate the activity of the protein tyrosine kinase. Also disclosed are methods of modulating the activity of a protein tyrosine kinase in a subject by administering one of the peptides of the present invention.

Abstract: Peptides which are peptide derivatives of the B4-5 region of a protein kinase can modulate the activity of protein kinases. The activity of a protein kinase in a subject can be modulated by administering one or more of these peptides.

Abstract: The present invention concerns methods for the treatment of metabolic-related diseases by the modulation of GRK associated signal transduction. Preferred in accordance with the invention are modulators which comprise sequences derived from specific regions of the GRK.

Abstract: The invention concerns a method for the modulation of tissue-remodeling processes, by contacting the tissue to be remodeled with a compound comprising a sequence derived from certain regions of TGF-&bgr; super family Ser/Thr/kinase receptors.

Abstract: Peptides which are peptide derivatives of the &agr;D region of a protein kinase can modulate the activity of protein kinases. The activity of a protein kinase in a subject can be modulated by administering one or more of these peptides.

Abstract: The present invention concerns methods for the treatment of prostate cancer by the inhibition of Lyn-kinase associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn-kinase.

Abstract: The present invention concerns compounds comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction.

Abstract: Peptides which are peptide derivatives of the A region of a protein kinase can modulate the activity of protein kinases. The activity of a protein kinase in a subject can be modulated by administering one or more of these peptides.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.

Abstract: Disclosed is a method for modulating metabolism in an individual. The method includes administering to the individual a substance, such as a GRK-derived HJ loop peptide, which alters activity of a GRK, wherein the administration of the substance results in an increase or decrease of the individual's metabolism. Also disclosed are GRK-derived HJ loop peptides.

Abstract: Prostate cancer can be treated by administering one or more inhibitros of lyn tyrosine kinase to an individual who has or is susceptible to contracting prostate cancer. The inhibitors include peptides containing between six and eleven amino acids.